Drug Approval | October 30, 2022
USFDA issues Form 483 for Parawada unit of Laurus Labs
The observation is procedural in nature and the company will address the observation within stipulated timelines.
The observation is procedural in nature and the company will address the observation within stipulated timelines.
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.
Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022
Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.
Merck is organizing one of the biggest South APAC Virtual Conclave on ‘Next-Gen Labs’ on 20th July.
The introduction of Enverse is part of StimLabs' aim to simplify patient care for both physicians and the hospital systems
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
Subscribe To Our Newsletter & Stay Updated
